Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway
出版年份 2018 全文链接
标题
Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway
作者
关键词
-
出版物
BIOSCIENCE REPORTS
Volume 38, Issue 6, Pages BSR20181693
出版商
Portland Press Ltd.
发表日期
2018-11-12
DOI
10.1042/bsr20181693
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7
- (2018) Zahra Shahsavari et al. Anti-Cancer Agents in Medicinal Chemistry
- LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
- (2018) Zhixian Fang et al. BIOMEDICINE & PHARMACOTHERAPY
- Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
- (2018) Namita Sharma et al. CANCER TREATMENT REVIEWS
- Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway
- (2018) Jian-cai Tang et al. LIFE SCIENCES
- Lung Cancer Biopsies
- (2018) Amita Sharma et al. RADIOLOGIC CLINICS OF NORTH AMERICA
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin
- (2018) Fan Ni et al. Scientific Reports
- Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- (2018) Jian-Cai Tang et al. Journal of Cancer
- Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression
- (2018) Hongming Zheng et al. Frontiers in Pharmacology
- Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer
- (2018) Qi Yang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition
- (2017) Yei-San Hsieh et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
- (2017) Honggang Wang et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers
- (2017) Christos Chouaid et al. Journal of Thoracic Oncology
- Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
- (2017) Toshimitsu Yamaoka et al. MOLECULAR CANCER RESEARCH
- Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- (2017) Xia Li et al. PHARMACOLOGICAL RESEARCH
- Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300
- (2016) Yun-Ji Jeung et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Shikonin Derivative DMAKO-05 Inhibits Akt Signal Activation and Melanoma Proliferation
- (2016) Yao-yao Yang et al. Chemical Biology & Drug Design
- PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
- (2016) D.-W. Wu et al. CLINICAL CANCER RESEARCH
- miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
- (2016) JING HAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest
- (2016) PENG-JUN ZHAO et al. Molecular Medicine Reports
- The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
- (2016) Laurence Booth et al. Oncotarget
- Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis
- (2016) Shuichuan Song et al. MEDICAL SCIENCE MONITOR
- Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
- (2016) XinHai Zhu et al. MEDICAL SCIENCE MONITOR
- Therapeutic potential of Ginsenoside Rg3 via inhibiting Notch/HES1 pathway in lung cancer cells
- (2016) Ruzhen Zheng et al. Translational Cancer Research
- γ Secretase Inhibitor BMS-708163 Reverses Resistance to EGFR Inhibitor via the PI3K/Akt Pathway in Lung Cancer
- (2015) Mian Xie et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling
- (2015) DAN LU et al. Oncology Letters
- FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
- (2015) Koichi Azuma et al. Oncotarget
- Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
- (2014) Yiqing Qu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Inhibition of cell proliferation by mild hyperthermia at 43°C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
- (2014) PENGJUN ZHAO et al. Molecular Medicine Reports
- Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo
- (2014) HAO JIANG et al. Molecular Medicine Reports
- Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1
- (2014) Yong-Dong Jin et al. PHARMACEUTICAL BIOLOGY
- Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
- (2014) Simona Coco et al. Targeted Oncology
- Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line
- (2014) HAO JIANG et al. Oncology Letters
- The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism
- (2013) Victor Jeannot et al. INTERNATIONAL JOURNAL OF CANCER
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now